pSivida announces presentations on bioerodible technologies for degenerative eye disease

Apr 30 2010

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of back of the eye drug delivery systems, today announced that two poster presentations will be made at the upcoming ARVO meeting on one of pSivida's next generation bioerodible technologies for degenerative eye disease. It marks a key step toward the ability to use pSivida's bioerodible technologies to develop treatments for glaucoma and other degenerative eye diseases, diseases that affect millions of Americans.

“We are encouraged by the results of these studies”

"Development of Bioerodible Sustained Release Brimonidine Intraocular Device" and "Evaluation of a Single Intravitreal Injection of Extended Release Brimonidine Impregnated Device in a Rabbit Eye" report successful pre-clinical results of the next generation Durasert™ devices as a means of delivering Brimonidine to the back of the eye over a three-month period.

"We are encouraged by the results of these studies," stated Dr. Paul Ashton, President and CEO of pSivida. "While glaucoma can be treated with daily or twice daily eye drops, patient compliance is an issue. Long term sustained delivery directly to the target site has the potential to mark a major shift in the treatment of glaucoma and other degenerative eye diseases."

Ashton noted that Durasert technology is also used in Iluvien® for the treatment of diabetic macular edema (DME), which has been licensed to Alimera Sciences. A new drug application (NDA) for Iluvien is expected to be submitted to the FDA in this quarter and, if approved, will mark the first drug treatment for this disease.

Other Presentations on Durasert Technologies

In addition to the posters being presented on the bioerodible system, there will be seven additional presentations on Durasert technologies, including Retisert® and Iluivien.

Dr. Ashton said "In addition to the three presentations on studies sponsored by pSivida and its partners, we are pleased that there are six poster presentations by independent researchers of additional studies involving pSivida's technologies. These will be delivered by doctors from well known institutions."